NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs062180027

Registered date:26/02/2019

The development of treatment using neurofeedback (NFB) for patients with mood disorder

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedMood disorders (major depressive disorder and bipolar disorder) and healthy volunteers
Date of first enrollment29/01/2016
Target sample size130
Countries of recruitmentJapan only,Japan
Study typeInterventional
Intervention(s)For depressive patients, conducting NFB training to control regional brain activities associated with major depressive disorder or to improve higher cognitive functions, such as attention and working memory, whose improvement are thought to be effective against mood disorders. For healthy-control individuals, establish feasibility of neurofeedback training to control regional activities associated with mood disorders. In addition, examining potentials as an alternative medicine of NFB training on cognitive functions such as attention and working memory whose improvement are thought to be effective against mood disorders.

Outcome(s)

Primary OutcomeFor patients with mood disorders, 1) Severity assessment of mood disorders: evaluate changes after each session by PANAS, and changes after all the sessions by HRSD or BDI-II. 2) Assessment of changes in brain activity associated with the treatment effects: evaluate changes in brain activity (changes in signals of each brain region on fMRI, EEG and NIRS before and after the treatment) associated with the treatment effects, such as in severity of mood disorders (assessed by HRSD or BDI-II). For healthy controls, 3) Viability assessment of manipulation of neural activity: evaluate the desired brain activity or functional connectivity patterns by brain functional imaging to check whether they can be induced or not.
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum< 80age old
GenderBoth
Include criteria[For patients/clients ] 1) Aged 20-80 years old 2) Being diagnosed as major depressive disorder or bipolar disorder (Type I, Type II) according to DSM-IV-TR or DSM-V criteria 3) Present ongoing episode of major depressive symptoms 4) Present treatment-resistance (scores 14 points or above out of 17 items on the Hamilton Rating Scale for Depression even after >=4 weeks of treatment with sufficient amount of more than 1 kinds of anti-depressants) or low treatment-tolerance (insufficient administration due to side-effects while taking more than 1 kinds of anti-depressants) 5) Satisfactory informed consent obtained from the participant him/herself [For healthy control] 1) Aged 20-80 years old 2) Not history of psychiatric disorders 3) Not having current serious medical illness Satisfactory informed consent obtained from the participant him/herself
Exclude criteria1) Decisionally impaired individuals who has diminished capacity to understand the aim of the research 2) Physically impaired individuals who are not able to complete the experiment 3) Subjects who are contraindicated for the use of MRI Having an implanted heart pace-maker Having implanted cerebral (arteries) clips Having implanted neural/nerve stimulators Having implanted pumps Having work experience in a metal industry or possibility of metal residues remaining in the body Having metal-tattoos (including tattooed eye-lining) Being pregnant, or having possibility of being pregnant 4) Any individuals judged as inappropriate for the experiment by the principal investigator or a collaborating researcher. 5)Those participating in other intervention studies

Related Information

Contact

Public contact
Name Go Okada
Address 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-8551,JAPAN Hiroshima Japan 734-8551
Telephone +81-82-257-5814
E-mail goookada@hiroshima-u.ac.jp
Affiliation Hiroshima University
Scientific contact
Name Go Okada
Address 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-8551,JAPAN Hiroshima Japan 734-8551
Telephone +81-82-257-5814
E-mail goookada@hiroshima-u.ac.jp
Affiliation Hiroshima University Hospital